On-To The Moon - Tiger Brokers Online Investing Community - To The Moon

1
Comment
Favorite

Kanyon
2022-03-29

On

Novo Nordisk's Ozempic Drug Gets FDA Approval for 2 Milligram Dose to Treat Type 2 Diabetes

Danish pharmaceutical company Novo Nordisk AS said late Monday that the U.S. Food and Drug Administr

Novo Nordisk's Ozempic Drug Gets FDA Approval for 2 Milligram Dose to Treat Type 2 Diabetes

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1

Report

Comment

Top
Latest

Kanyon
·2022-03-29
Ok
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9019340818,"tweetId":"9019340818","gmtCreate":1648541647176,"gmtModify":1676534351950,"author":{"id":3567979712068924,"idStr":"3567979712068924","authorId":3567979712068924,"authorIdStr":"3567979712068924","name":"Kanyon","avatar":"https://static.tigerbbs.com/5b4865bae805415342780f86469a2ba7","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":17,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>On</p></body></html>","htmlText":"<html><head></head><body><p>On</p></body></html>","text":"On","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9019340818","repostId":1125847128,"repostType":4,"repost":{"id":"1125847128","kind":"news","pubTimestamp":1648538304,"share":"https://www.laohu8.com/m/news/1125847128?lang=&edition=full","pubTime":"2022-03-29 15:18","market":"us","language":"en","title":"Novo Nordisk's Ozempic Drug Gets FDA Approval for 2 Milligram Dose to Treat Type 2 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=1125847128","media":"MarketWatch","summary":"Danish pharmaceutical company Novo Nordisk AS said late Monday that the U.S. Food and Drug Administr","content":"<html><head></head><body><p>Danish pharmaceutical company <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk AS</a> said late Monday that the U.S. Food and Drug Administration has approved a 2.0 milligram dose of its Ozempic drug to treat adults with type 2 diabetes.</p><p>Ozempic is now approved in the U.S. at 0.5 milligram, 1.0 milligram and 2.0 milligram doses for the treatment of type 2 diabetes in adults, it added.</p><p>In addition, Ozempic is indicated to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease, the company said.</p><p>Novo Nordisk expects to launch Ozempic 2.0 milligram in the U.S. in the second quarter of 2022.</p><p>Ozempic 2.0 milligram is now approved in the U.S., the EU, Canada and Switzerland.</p><p></p></body></html>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk's Ozempic Drug Gets FDA Approval for 2 Milligram Dose to Treat Type 2 Diabetes </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk's Ozempic Drug Gets FDA Approval for 2 Milligram Dose to Treat Type 2 Diabetes \n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-03-29 15:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/novo-nordisk-s-ozempic-drug-gets-fda-approval-for-2-milligram-dose-to-treat-type-2-diabetes-271648537203?mod=newsviewer_click><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Danish pharmaceutical company Novo Nordisk AS said late Monday that the U.S. Food and Drug Administration has approved a 2.0 milligram dose of its Ozempic drug to treat adults with type 2 diabetes....</p>\n\n<a href=\"https://www.marketwatch.com/story/novo-nordisk-s-ozempic-drug-gets-fda-approval-for-2-milligram-dose-to-treat-type-2-diabetes-271648537203?mod=newsviewer_click\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德"},"source_url":"https://www.marketwatch.com/story/novo-nordisk-s-ozempic-drug-gets-fda-approval-for-2-milligram-dose-to-treat-type-2-diabetes-271648537203?mod=newsviewer_click","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125847128","content_text":"Danish pharmaceutical company Novo Nordisk AS said late Monday that the U.S. Food and Drug Administration has approved a 2.0 milligram dose of its Ozempic drug to treat adults with type 2 diabetes.Ozempic is now approved in the U.S. at 0.5 milligram, 1.0 milligram and 2.0 milligram doses for the treatment of type 2 diabetes in adults, it added.In addition, Ozempic is indicated to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease, the company said.Novo Nordisk expects to launch Ozempic 2.0 milligram in the U.S. in the second quarter of 2022.Ozempic 2.0 milligram is now approved in the U.S., the EU, Canada and Switzerland.","news_type":1},"isVote":1,"tweetType":1,"viewCount":387,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":100997715,"commentId":"100997715","gmtCreate":1648541658054,"gmtModify":1663245905344,"authorId":3567979712068924,"author":{"id":3567979712068924,"idStr":"3567979712068924","authorId":3567979712068924,"name":"Kanyon","avatar":"https://static.tigerbbs.com/5b4865bae805415342780f86469a2ba7","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9019340818,"objectIdStr":"9019340818","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Ok","text":"Ok","html":"Ok","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}